Roth Capital raised the firm’s price target on PolyPid (PYPD) to $10 from $9 and keeps a Buy rating on the shares after meeting with its management following the company’s Q2 results. The firm expects a fairly uneventful pre-NDA meeting given solid D-PLEX100 clinical data, which Roth believes is poised to transform the treatment paradigm in SSI associated with colorectal cancer surgery, providing benefits to patients and healthcare systems, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid Reports Strong Phase 3 Results and Financial Update
- PolyPid Releases Mid-2025 Financial Update
- PolyPid’s Promising Outlook: Buy Rating Affirmed Amidst Positive Phase 3 Results and Strategic Advancements
- PolyPid Reports Positive Phase 3 Results and Strengthens Leadership
- PolyPid reports Q2 EPS (78c), consensus (55c)